Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

NCT01652716 · Completed

Last updated 2026-05-28

This clinical trial tested a once-weekly injectable medication called exenatide in adults with type 2 diabetes to see how it affects blood sugar levels over 28 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 377 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-01 · est. completion 2014-08

Where 58 sites · United States

What this study is testing ClinicalTrials.gov NCT01652716 ↗

Description as written by the study sponsor.

To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. To examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.

Treatments tested

Exenatide once weekly suspension Drug

Exenatide suspension 2 mg weekly subcutaneous injection
Exenatide twice daily also known as Byetta Drug

5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks

Main thing measured	Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01652716 ↗